跳至主要内容
临床试验/JPRN-jRCT1021230006
JPRN-jRCT1021230006招募中Unknown

A multi-center retrospective observational study of effectiveness, safety and treatment status of tirabrutinib in relapsed or refractory pcnsl (ROSETTA) - ROSETTA Study

agane Motoo0 个研究点目标入组 206 人开始时间: 2023年5月21日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
206

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Patients diagnosed with relapsed or refractory PCNSL and started initial treatment with tirabrutinib between November 1, 2020 and April 30, 2022, and who were enrolled in a Post Marketing Surveillance

排除标准

  • 1. Patients with PCNSL who had not recieved drug therapy
  • 2. Patients with metastasis outside the central nervous system, excluding intraocular, at the time of starting the first tirabrutinib treatment
  • 3. Patients diagnosed with secondary central nervous system lymphoma (SCNSL)
  • 4. Patients who had participated in clinical studies involving other interventions between the first PCNSL diagnosed and the start of the first tirabrutinib treatment. However, among patients who had participated in clinical research involving intervention, patients who recieved treatment within the indications of PCNSL treatment can be enrolled in this study.
  • 5.Patients who weren't perscribed 480 mg of tirabrutinib once daily in fasted condition at the start of treatment

研究者

发起方
agane Motoo

相似试验